Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
03/2003
03/12/2003CN1401321A Pharmaceutic composition of anti-platelet aggregation
03/12/2003CN1401317A Use of bismuth subgallate in suppressing formation of nitrogen oxide synthetase
03/12/2003CN1102851C Plasma like solution
03/12/2003CA2422067A1 Aminoheterocycles (factor xa inhibitors 14)
03/11/2003US6531492 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
03/11/2003US6531490 Production of agglomerates of inogatran and the compound inogatran anhydrate
03/11/2003US6531474 Inhibitors of caspases
03/11/2003US6531468 Inhibiting serotonin reuptake in the central nervous system of a mammal
03/07/2003WO2002020472A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/07/2003CA2421781A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
03/06/2003WO2003019198A2 Methods relating to treatment of atherosclerosis
03/06/2003WO2003019196A2 Diagnosis and treatment of atherosclerosis
03/06/2003WO2003018784A1 Process for producing antigen-specific human t cells and drugs
03/06/2003WO2003018756A2 Methods for preparing purified prostaglandin e synthase
03/06/2003WO2003018640A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003WO2003018639A1 Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods, especially for use as a plasma volume expander
03/06/2003WO2003018606A2 Casein derived peptides and uses thereof in therapy
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018551A1 New mandelic acid derivatives and their use as thrombin inhibitors
03/06/2003WO2003018539A1 Amphoteric lipid compound and use thereof
03/06/2003WO2003018032A1 Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003018016A1 Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion
03/06/2003WO2003017992A2 Means for treatment of atherosclerosis
03/06/2003WO2003017987A1 Biodegradable polymeric nanocapsules and uses thereof
03/06/2003WO2003017983A1 A new extended release oral dosage form
03/06/2003WO2003017982A1 A new extended release oral dosage form
03/06/2003WO2003017919A2 Composition comprising wenguanguo extracts, methods for preparing same and uses therof
03/06/2003WO2002101021A3 Purification of human serum albumin
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002074249A3 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002063961B1 Composition and methods for modulation of vascular structure and/or function
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002046160A3 Process for making a thrombin inhibitor
03/06/2003WO2002024672A3 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
03/06/2003WO2002004423A8 Thrombin inhibitors comprising an aminoisoquinoline group
03/06/2003US20030045728 Indol-3-yl derivatives
03/06/2003US20030045602 Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
03/06/2003US20030045586 Use of amines
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045560 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
03/06/2003US20030045517 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045505 Oligosaccharide having at least a D-galactose unit bound by an alpha (1-6) bond with a sucrose unit; second component is a molecule positively charged at physiological pH and that promotes pinocytosis or membrane penetration
03/06/2003US20030045493 Oligonucleotide compositions and their use to induce differentiation of cells
03/06/2003US20030045481 Use of specific amino acids reduces or prevents coloration attributable to a saccharide stabilizer; especially useful in pharmacologically active proteinaceous compositions
03/06/2003US20030045449 Pharmaceutical combinations for the treatment of neurodegenerative diseases
03/06/2003US20030044975 Cytokine-binding domain for use in the treatment of asthma and thrombocytopenia
03/06/2003US20030044893 Nectin polypeptides, polynucleotides, methods of making and use thereof
03/06/2003US20030044514 Using supercritical fluids to infuse therapeutic on a medical device
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030042202 Low molecular weight thrombin inhibitors
03/06/2003CA2458924A1 Casein derived peptides and uses thereof in therapy
03/06/2003CA2458852A1 Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2457846A1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003CA2457341A1 A new extended release oral dosage form
03/06/2003CA2457339A1 A new extended release oral dosage form
03/06/2003CA2451740A1 Composition comprising wenguanguo extracts, methods for preparing same and uses thereof
03/05/2003WO2002020566A2 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3?
03/05/2003EP1288264A1 Gelling composition
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288222A1 Peptidic compounds selectively binding to P-selectin
03/05/2003EP1288206A1 Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
03/05/2003EP1287355A2 Methods and compounds for influencing $g(b)3 integrin-dependent intracellular processes
03/05/2003EP1287349A2 Method and apparatus for monitoring anti-platelet agents
03/05/2003EP1287142A1 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide
03/05/2003EP1287120A2 Human circulating dendritic cell compositions and methods
03/05/2003EP1287035A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
03/05/2003EP1287020A2 Cancer diagnosis and assays for screening anti-cancer agents
03/05/2003EP1287018A2 Thrombin inhibitors
03/05/2003EP1287017A1 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
03/05/2003EP1287015A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
03/05/2003EP1286989A2 Prodrug of an ice inhibitor
03/05/2003EP1286982A2 Process for the preparation of benzoyl substituted bicylic compounds and chiral bnezopyran derivatives
03/05/2003EP1286973A2 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
03/05/2003EP1286962A1 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
03/05/2003EP1286703A2 Methods and compounds for controlled release of recombinant parvovirus vectors
03/05/2003EP1286693A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
03/05/2003EP1286691A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
03/05/2003EP1286690A2 Use of alpha-msh and epo for preventing or treating ischemic conditions
03/05/2003EP1286689A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
03/05/2003EP1286673A2 Ligands of integrin receptors
03/05/2003EP0892791B1 N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS
03/05/2003CN1400974A Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors
03/05/2003CN1400973A Novel biarylcarboxamides
03/05/2003CN1400910A Factor VII or VIIa like molecules
03/05/2003CN1399998A Chinese medicine prescription for reducing blood fat and dissolving thrombus
03/05/2003CN1399976A Chinese medicine powder preparation for resisting thrombosis and its preparation method
03/05/2003CN1399957A Application of shikonin and its derivative in pharmaceutical industry
03/05/2003CN1102660C Antihumanfibrin monoclonal antibody heavy chain and light chain variable region gene and its application
03/05/2003CN1102393C Pharmaceutical composition containing selected lanthanum carbonate hydrates
03/05/2003CN1102391C Crystalline pharmaceutical product
03/05/2003CA2421283A1 Novel mmp-2 derivatives for use as inhibitors of integrin .alpha.v.beta.3
03/04/2003US6528534 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
03/04/2003US6528509 Pyrazole compositions useful as inhibitors of ERK
03/04/2003US6528508 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli
1 ... 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 ... 671